Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together...
Leider schon ausverkauft
234.99 €
versandkostenfrei
117 DeutschlandCard Punkte
sammeln
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
- Ratenzahlung möglich
Produktdetails
Produktinformationen zu „Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy “
Weitere Produktinformationen zu „Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy “
Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials.
Bibliographische Angaben
- Herausgegeben:Bonavida, Benjamin; Chen, Zhe-Sheng (Jason); Yang, Dong-Hua
- Verlag: Academic Press
- EAN: 9780128164358
Autoren-Porträt
Benjamin Bonavida, PhD, has been involved in the field of immunology and cancer biology for several decades and has published extensively in the fields of cancer resistance, chemotherapy, immunotherapy, and various molecular approaches to circumvent the resistance of the cancer cells using sensitizing agents. Accordingly, he was the first to publish a book on tumor sensitization in 2008. More recently, Dr. Bonavida is the Series Editor of 3 series published by Elsevier/Academic Press ("Cancer Sensitizing Agents for Chemotherapy,? "Breaking Cancer Resistance to Therapeutic Antibodies,? and "Breaking Tolerance to Anti-Cancer Immunotherapy?) and several books have been published and many are in development. He has published extensively in the field of NK biology and cytotoxicity in the past, and many of these publications were in collaboration with the co-editor Dr. Anahid Jewett.Zhe-Sheng Chen opened the St. John's University's first cancer pharmacology laboratory. His research interest is multidrug resistance and its reversal, novel anti-cancer drug development. Chen serves as Editor of "African Journal of Pharmacy and Pharmacology"; Editor-in-Chief of "Journal of Cancer Research Updates" and "Journal of New Developments in Chemistry". He also serves as an Editorial Board member of 25 journals, an Ad Hoc reviewer of 180 journals, and a guest editor of "Current Pharmaceutical Biotechnology", "Cancer" and "Journal of International Medical Research". Chen has over 170 papers published, 6 book chapters, and 5 patents.
Inhaltsverzeichnis zu „Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy “
1. EGFR and HER2 inhibitors as sensitizing agents for cancer chemotherapy 2. BCR-ABL inhibitors as sensitizing agents for cancer chemotherapy 3. VEGFR inhibitors as sensitizing agents for cancer chemotherapy 4. ALK inhibitors as sensitizing agents for cancer chemotherapy 5. JAK2 inhibitors as sensitizing agents for cancer chemotherapy 6. FLT3 inhibitors as sensitizing agents for cancer chemotherapy 7. BRAF inhibitors as sensitizing agents for cancer chemotherapy 8. Bruton kinase inhibitors as sensitizing agents for cancer chemotherapy
Kommentar zu "Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy"
0 Gebrauchte Artikel zu „Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy".
Kommentar verfassen